Colgate-Palmolive Q2 Results Beat Street; Sees FY25 Organic Sales Growth At Low End Of Target Range

Colgate-Palmolive (CL) reported second-quarter adjusted earnings of $0.92 per share and revenue of $5.11 billion, both surpassing analyst expectations, which contributed to a 1.3% pre-market share gain. While maintaining its fiscal 2025 earnings and net sales growth guidance at low single digits, the company narrowed its organic sales growth forecast to the low end of its 2-4% range, partly due to a planned exit from private label pet sales. Additionally, CL announced a new three-year productivity program, anticipating $200-$300 million in pre-tax charges by 2028, aimed at driving future growth.

Analysis

Colgate-Palmolive reported a solid second quarter, with adjusted earnings of $0.92 per share and revenue of $5.11 billion, both surpassing analyst estimates and contributing to a 1.3% pre-market share price increase. The 1.8% organic sales growth, however, signals a moderated pace. While the company maintained its core fiscal 2025 guidance for low single-digit growth in both earnings per share and net sales, it tempered expectations by forecasting organic sales growth at the low end of its 2% to 4% range. This revision is attributed to specific headwinds, including the planned exit from private label pet sales, the impact of tariffs, and a flat to low-single-digit negative impact from foreign exchange. Concurrently, Colgate-Palmolive has initiated a new three-year productivity program aimed at long-term growth, which will incur an estimated $200 to $300 million in pre-tax charges through 2028, signaling a strategic reinvestment at the cost of near-term expenses.

Key Decisions for Investors

• Investors should weigh the positive Q2 earnings beat against the more cautious forward guidance, particularly the revised organic sales growth forecast which now sits at the low end of the 2-4% range.
• Monitor the execution of the new three-year productivity program, as its success in driving future growth will need to justify the $200-$300 million in associated charges over the next few years.
• Closely track the material impact of identified headwinds, including foreign exchange rates, tariffs, and the financial consequences of exiting the private label pet sales business on future earnings reports.